PetVivo Holdings, Inc.’s (NASDAQ: PETV) interview, Mr. John Lai, CEO & President


The New to The Street T.V. show airs the in-studio NASDAQ interview with Mr. John Lai, CEO & President, PetVivo Holdings, Inc. (NASDAQ: PETV). Talking with T.V.’s Host Jane King, Mr. Lai gives an overview of the Company’s biomedical devices and its osteoarthritis treatment available to millions of dogs and horses. With about 17 new products in development at the Company, Mr. Lai gives examples of various products used for humans. PETV’s vascular shunts show no clotting problems, a typical issue with current products in use. Another product development, their vascular stent, shows no thrombosis issues after 30-days of being applied, a specific problem related to existing products currently in the marketplace. At the recent veterinary conference in Las Vegas, John’s says the Company’s received very well. And at the Emerging Growth Conference, another attended venue allowed the Company to inform shareholders, potential shareholders, and industry professionals about the Spryng™ with OsteoCushion™ Technology injection. He explains how the US FDA views treatments and applications between humans and animals and the fundamental difference on a regulatory basis. He tells views to expect a feline product for cat pet owners, another multibillion-dollar market for the Spryng™ injection to gain recognition with cat owners as it has done with both dogs and horse owners. The Company recently hired Mr. Joe Manning, a past executive at the animal health division at Merck. PETV looks forward to his experience and business acumen, assisting the Company with its increasing growth.

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:
Follow New to the Street on Facebook:
Follow New to the Street on Instagram:
Follow New to the Street on Rumble:
About New to the Street:

Subscribe to our Mailing List: